

Factsheet | The Value Added Medicines Group



About the Value Added Medicines Group

The **Value Added Medicines Group**, a sector group of **Medicines for Europe** aims to rethink, reinvent and optimise medicines based on known molecules by bringing untapped innovation to improve care delivery. The **Value Added Medicines Group** adopts a complementary perspective compared to the other **Medicines for Europe** sector groups by tackling the targeted portion of patient needs that remain unmet to this day, delivering additional improvements to the healthcare community as a whole.



Medicines for Europe represents the European generic, biosimilar and value added medicines industries, which provide high-quality cost-competitive medicines to millions of Europeans. The vision of **Medicines for Europe** is to provide sustainable access to high quality medicines for all European patients, based on 5 important pillars: patients, quality, value, sustainability and partnership.

The **Value Added Medicines Group** is open to pharmaceutical companies interested in developing this industrial sector. Existing **Medicines for Europe** members benefit from a membership fee reduction.

For more information please follow us at www.medicinesforeurope.com and on Twitter [@medicinesforEU](https://twitter.com/medicinesforEU)

Our Vision & Mission

VISION: By rethinking, reinventing and optimising existing medicines, we aim to provide European patient access to value added medicines, delivering considerable outcomes for patients, healthcare professionals and payers over existing alternatives.

MISSION: Establish, in collaboration with patients, healthcare professionals and payers, a sustainable market model that incentivises R&D and access to value added medicines in Europe.

Value Added Medicines Group Membership

Companies

3M
Accord
Healthcare
Alfred E. Tiefenbacher
Camargo
Consilient Health Ltd
DSM

EGIS
Fresenius Kabi
Medichem
Mylan
OJER Pharma
Oncomed
PharOS

Polpharma
Sandoz
Teva
Theranexus
Zentiva

Associations

GEMME (France)
IEIS (Turkey)
GENAS (Slovakia)
MAGYOSZ (HU)
Medaxes (BE)
VGA (LT)

5 pillars

Patients



The **Value Added Medicines Group** sees value added medicines as an opportunity to understand and support patient needs. The improvement of treatments containing known molecules should ultimately deliver additional health benefits and help patients to better manage their health condition. The **Value Added Medicines Group** is developing a framework to unlock new opportunities to help patients in their healing process, offering more adapted medicines to those who need it.

Quality



The **Value Added Medicines Group** is dedicated to providing better access to high quality care. At a time where the concept of universal access to quality care and innovation is under pressure, value added medicines enable the healthcare system to reap the benefits of innovation without compromising equitable access to tailored treatment.

Value



Value added medicines aim to bring innovation continuously throughout a molecule's lifecycle, particularly those molecules no longer protected by patent. Working with proven compounds whose toxicity and other effects have been studied, can reduce development times. However, to combine new technologies with known molecules requires considerable R&D investment and effort. The ambition of the **Value Added Medicines Group** is to play a leading role in unlocking this new and untapped research potential, focusing on existing molecules.

Sustainability



Healthcare inefficiencies represent opportunities to optimise and rethink current health delivery systems as well as reinvent current therapies in a context where patients are more empowered on all aspects of their health and related well-being. In this frame, the **Value Added Medicines Group** comes forward with an answer to bring innovative healthcare while preserving system sustainability.

Partnership



The **Value Added Medicines Group** engages with the healthcare community and policy makers to support greater access to medicines and to medicines innovation for all European patients. Recognising that healthcare systems are under considerable financial strain, we encourage greater collaboration between stakeholders. We recognise that patients, healthcare professionals and payers have existing needs and expect genuine improvement, more innovation and sustainable access models in the future.